CD274 and lung carcinoma: Other PD-1/PD-L1 pathway-targeting ICBs approved for specific subsets of lung cancer patients include atezolizumab (NSCLC and SCLC patients) including as a first-line therapy, durvalumab (advanced NSCLC), and nivolumab (advanced NSCLC and a subset of metastatic SCLC as described above) (49, 129–131).